Literature DB >> 7678714

Fazarabine: a report of response in a patient with multiply relapsed embryonal cell carcinoma.

P G Johnston1, D Kleiner, K H Cowan.   

Abstract

This report describes a patient with multiply relapsed and advanced metastatic embryonal cell carcinoma who achieved a pathological partial remission (PR) following treatment with a Phase I chemotherapeutic agent, arabinosyl-5-azacytosine (Ara-AC), followed by orchiectomy. The antimetabolic Ara-AC is worthy of further study in patients with germ-cell tumors. It would appear that the antimetabolite Ara-AC may have significant activity in patients with germ-cell tumors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678714

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  1 in total

1.  A phase I trial of fazarabine in refractory pediatric solid tumors. A Pediatric Oncology Group study.

Authors:  M L Bernstein; V M Whitehead; H Grier; R Dubowy; V Land; S Devine; S Murphy; F Kung
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.